This company is primarily_engaged in the manufacture of novel CRIMINAL_CHARGE for CAUSE_OF_DEATH. The company was_incorporated in DATE, and has its_registered_head office in CITY,_California.The company aims_to produce novel protein therapeutics to_treat CAUSE_OF_DEATH and other debilitating CAUSE_OF_DEATH in humans. It has_established_partnerships with : ORGANIZATION ORGANIZATION ORGANIZATION ORGANIZATION ; ORGANIZATION ORGANIZATION ; ORGANIZATION CITY ; and ORGANIZATION CITY. The company has a cGMP facility to_produce novel protein therapeutics to support clinical_trials at various_stages in the COUNTRY, LOCATION, and the LOCATION_LOCATION_LOCATION region. Its lead project, PEGylated Arginine Deiminase (ADI - PEG NUMBER), is in clinical_trials for patients_with hepatocellular carcinoma, non-small cell CAUSE_OF_DEATH_CAUSE_OF_DEATH, CAUSE_OF_DEATH,_CAUSE_OF_DEATH, CAUSE_OF_DEATH_CAUSE_OF_DEATH, CAUSE_OF_DEATH_CAUSE_OF_DEATH, CAUSE_OF_DEATH,_CAUSE_OF_DEATH, and CAUSE_OF_DEATH_CAUSE_OF_DEATH. The company manufactures all CRIMINAL_CHARGE for global clinical studies conducted by ORGANIZATION ORGANIZATION ORGANIZATION is a_subsidiary of ORGANIZATION ORGANIZATION, a multinational biotechnology company focused_on_developing novel anti-cancer therapies.